Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Recent advances in advanced melanoma: ipilimumab (2/6)

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.08.11
Views: 5901

European Post ASCO Meeting 2011 - Prof Axel Hauschild, Prof Michele Maio, Prof Paul Lorigan, Prof Dirk Schadendorf

Research presented at the 2011 ASCO congress has demonstrated that the anti-CTLA4 antibody ipilimumab improve overall survival in both previously untreated melanoma patients and those receiving second line therapy. Ipilimumab acts by reducing natural inhibition of the immune system, causing the body to attack cancer cells more aggressively. This allows the body to stabilise the disease and prevent tumour growth. These effects are targeted at the immune system and consequently the associated adverse effects are quite different to those caused by drugs which target cancer cells. The panel outline the side effects seen in patients treated with ipilimumab, explain how clinicians have learnt to manage these effects and discuss how cost is likely to affect the chance of ipilimumab approval in various European countries.

Related videos

follow us

WIN 2019

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation